Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

AO Sokolova, CH Marshall, R Lozano, R Gulati… - The …, 2021 - Wiley Online Library
Background Among men with metastatic prostate cancer, about 10% have germline
alterations in DNA damage response genes. Most studies have examined BRCA2 alone or …
被引用次数：14 相关文章

Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

AO Sokolova, CH Marshall, R Lozano… - The …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Among men with metastatic prostate cancer, about 10% have germline
alterations in DNA damage response genes. Most studies have examined BRCA2 alone or …

Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.

AO Sokolova, CH Marshall, R Lozano, R Gulati… - The Prostate, 2021 - europepmc.org
Background Among men with metastatic prostate cancer, about 10% have germline
alterations in DNA damage response genes. Most studies have examined BRCA2 alone or …

Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

AO Sokolova, CH Marshall, R Lozano, R Gulati… - Prostate, 2021 - pure.johnshopkins.edu
Background: Among men with metastatic prostate cancer, about 10% have germline
alterations in DNA damage response genes. Most studies have examined BRCA2 alone or …

[引用][C] Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

AO Sokolova, CH Marshall, R Lozano, R Gulati… - Prostate, 2021 - portalcientifico.uah.es
Background: Among men with metastatic prostate cancer, about 10% have germline
alterations in DNA damage response genes. Most studies have examined BRCA2 alone or …
[HTML] nih.gov

[HTML][HTML] Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

AO Sokolova, CH Marshall, R Lozano, R Gulati… - The Prostate, 2021 - ncbi.nlm.nih.gov
Background: Among men with metastatic prostate cancer, about 10% have germline
alterations in DNA damage response genes. Most studies have examined BRCA2 alone or …
[HTML] umn.edu

[HTML][HTML] Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

AO Sokolova, CH Marshall, R Lozano, R Gulati… - Prostate, 2021 - experts.umn.edu
BACKGROUND: Among men with metastatic prostate cancer, about 10% have germline
alterations in DNA damage response genes. Most studies have examined BRCA2 alone or …

Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

AO Sokolova, CH Marshall, R Lozano, R Gulati… - Prostate, 2021 - ohsu.elsevierpure.com
Background: Among men with metastatic prostate cancer, about 10% have germline
alterations in DNA damage response genes. Most studies have examined BRCA2 alone or …

Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

AO Sokolova, CH Marshall, R Lozano, R Gulati… - The Prostate, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Among men with metastatic prostate cancer, about 10% have germline alterations in DNA …

[引用][C] Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

AO Sokolova, CH Marshall, R Lozano, R Gulati… - Prostate, 2021 - portalcientifico.uah.es